Market Cap 5.75B
Revenue (ttm) 627.24M
Net Income (ttm) -177.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28.22%
Debt to Equity Ratio 0.30
Volume 1,348,500
Avg Vol 1,351,400
Day's Range N/A - N/A
Shares Out 184.57M
Stochastic %K 30%
Beta 0.17
Analysts Strong Sell
Price Target $75.09

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 317 5050
Address:
2101 Cottontail Lane, Somerset, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:53 AM
$LEGN is currently in a bearish market context, indicated by its last close of $30.29, which is below both the 30-day moving average (MA30) of $32.08 and the 50-day moving average (MA50) of $32.64. The RSI at 31.21 suggests that the stock is oversold, indicating a potential for a rebound, but the overall trend remains downward. The recent high of $36.8 and low of $29.92 creates a range that suggests volatility; however, the stock is closer to the lower end of this range. Suggested trade plan: - Entry: $30.50 (slightly above the last close to confirm upward momentum) - Stop: $29.80 (below the recent low to limit risk) - Target 1: $32.00 (near the MA30) - Target 2: $32.50 (just below the MA50) This plan allows for a cautious approach while acknowledging potential upward movement. https://privateprofiteers.com
0 · Reply
Theflash88
Theflash88 Nov. 14 at 9:56 PM
$LEGN Time to sell or get new management.
0 · Reply
deedeethegenius
deedeethegenius Nov. 14 at 8:37 PM
M&a tier 1 $VKTX $LEGN $BL $TRIP $WBD
1 · Reply
DiamondHandsBTW
DiamondHandsBTW Nov. 14 at 5:57 PM
$LEGN almost 1 billion dollars in cash why arnt we doing share buybacks at these levels or buying pre clinical companies???
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Nov. 14 at 5:52 PM
$LEGN this company needs an activist to step in.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 14 at 3:01 PM
$SNDX $URGN $JAZZ & $LEGN trade at the lowest Year 4/FY2029 revenue multiples in all of commercial-stage oncology focused bio with market caps north of $1B This is not investment advice. The attachment notes FY29 & cumulative FY26 - FY29 revenue multiples of all bios in this peer group using intra-day valuations on 11/14/25. Revenue forecasts are per Seeking Alpha (number of analysts in consensus noted). The average bio in this peer group trades at 2.7X FY2029 analyst consensus revenue estimates (median = 2.2). It's our experience revenue multiples provide a barometer of valuation potential. This schedule does not include $KURA as we understand KURA forecasts are being updated to eliminate discounted forecasts (due to uncertainty around approval).
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:26 AM
$LEGN: The last close at $31.01 indicates a position near the lower end of the 60-day range (29.92 - 36.8). The RSI at 40.36 suggests the stock is approaching oversold territory, indicating potential for a bullish reversal. The current price is below both the 30-day MA (32.14) and the 50-day MA (32.76), which typically signals bearish momentum; however, the proximity to the 60-day low may provide support. Directional bias is cautiously bullish due to the RSI and the potential for a rebound from the low range. Suggested entry is at $31.50, slightly above the last close to confirm upward momentum. Set a stop loss at $29.80 to manage risk below the 60-day low. Target 1 is $33.00, aligning with the 30-day MA, and Target 2 is $34.50, reflecting a potential retracement towards the mid-range of the 60-day high-low. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 8:29 PM
Barclays has updated their rating for Legend Biotech ( $LEGN ) to Overweight with a price target of 90.
0 · Reply
prismmarketview
prismmarketview Nov. 13 at 7:06 PM
(NASDAQ: $LEGN) Legend Biotech has opened a new 31,000-square-foot state-of-the-art cell therapy research and development center in Philadelphia’s Center City, aimed at advancing its portfolio of next-generation cell therapies. https://prismmarketview.com/legend-biotech-expands-u-s-footprint-with-opening-of-new-state-of-the-art-cell-therapy-rd-center-in-philadelphia/
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 5:36 PM
RBC Capital has updated their rating for Legend Biotech ( $LEGN ) to Outperform with a price target of 74.
0 · Reply
Latest News on LEGN
Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 18, 2025, 8:00 AM EDT - 3 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer


Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:15 AM EDT - 6 months ago

Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript


Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 12:06 PM EDT - 8 months ago

Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript


Legend Biotech: The Story Brightens

Dec 5, 2024, 2:14 PM EST - 1 year ago

Legend Biotech: The Story Brightens


Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®


Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia


PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:53 AM
$LEGN is currently in a bearish market context, indicated by its last close of $30.29, which is below both the 30-day moving average (MA30) of $32.08 and the 50-day moving average (MA50) of $32.64. The RSI at 31.21 suggests that the stock is oversold, indicating a potential for a rebound, but the overall trend remains downward. The recent high of $36.8 and low of $29.92 creates a range that suggests volatility; however, the stock is closer to the lower end of this range. Suggested trade plan: - Entry: $30.50 (slightly above the last close to confirm upward momentum) - Stop: $29.80 (below the recent low to limit risk) - Target 1: $32.00 (near the MA30) - Target 2: $32.50 (just below the MA50) This plan allows for a cautious approach while acknowledging potential upward movement. https://privateprofiteers.com
0 · Reply
Theflash88
Theflash88 Nov. 14 at 9:56 PM
$LEGN Time to sell or get new management.
0 · Reply
deedeethegenius
deedeethegenius Nov. 14 at 8:37 PM
M&a tier 1 $VKTX $LEGN $BL $TRIP $WBD
1 · Reply
DiamondHandsBTW
DiamondHandsBTW Nov. 14 at 5:57 PM
$LEGN almost 1 billion dollars in cash why arnt we doing share buybacks at these levels or buying pre clinical companies???
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Nov. 14 at 5:52 PM
$LEGN this company needs an activist to step in.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 14 at 3:01 PM
$SNDX $URGN $JAZZ & $LEGN trade at the lowest Year 4/FY2029 revenue multiples in all of commercial-stage oncology focused bio with market caps north of $1B This is not investment advice. The attachment notes FY29 & cumulative FY26 - FY29 revenue multiples of all bios in this peer group using intra-day valuations on 11/14/25. Revenue forecasts are per Seeking Alpha (number of analysts in consensus noted). The average bio in this peer group trades at 2.7X FY2029 analyst consensus revenue estimates (median = 2.2). It's our experience revenue multiples provide a barometer of valuation potential. This schedule does not include $KURA as we understand KURA forecasts are being updated to eliminate discounted forecasts (due to uncertainty around approval).
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:26 AM
$LEGN: The last close at $31.01 indicates a position near the lower end of the 60-day range (29.92 - 36.8). The RSI at 40.36 suggests the stock is approaching oversold territory, indicating potential for a bullish reversal. The current price is below both the 30-day MA (32.14) and the 50-day MA (32.76), which typically signals bearish momentum; however, the proximity to the 60-day low may provide support. Directional bias is cautiously bullish due to the RSI and the potential for a rebound from the low range. Suggested entry is at $31.50, slightly above the last close to confirm upward momentum. Set a stop loss at $29.80 to manage risk below the 60-day low. Target 1 is $33.00, aligning with the 30-day MA, and Target 2 is $34.50, reflecting a potential retracement towards the mid-range of the 60-day high-low. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 8:29 PM
Barclays has updated their rating for Legend Biotech ( $LEGN ) to Overweight with a price target of 90.
0 · Reply
prismmarketview
prismmarketview Nov. 13 at 7:06 PM
(NASDAQ: $LEGN) Legend Biotech has opened a new 31,000-square-foot state-of-the-art cell therapy research and development center in Philadelphia’s Center City, aimed at advancing its portfolio of next-generation cell therapies. https://prismmarketview.com/legend-biotech-expands-u-s-footprint-with-opening-of-new-state-of-the-art-cell-therapy-rd-center-in-philadelphia/
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 5:36 PM
RBC Capital has updated their rating for Legend Biotech ( $LEGN ) to Outperform with a price target of 74.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 2:08 PM
Cantor Fitzgerald has updated their rating for Legend Biotech ( $LEGN ) to Overweight with a price target of 75.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:32 AM
$LEGN: The last close at $32.03 is slightly below the 30-day moving average (MA30) of $32.23, indicating a neutral to bearish short-term trend. The RSI at 49.0 suggests that the stock is neither overbought nor oversold, reinforcing a lack of strong directional momentum. The 50-day moving average (MA50) at $32.93 further indicates resistance above the current price. Given the 60-day high of $37.49 and low of $30.77, the stock is currently trading within this range, suggesting potential for a bounce back towards the upper end. Suggested entry: $32.10 (slightly above the last close). Stop: $30.70 (below the recent low). Targets: $34.00 (first target) and $36.00 (second target), aligning with resistance levels and potential retracement. Monitor market conditions closely as the stock approaches these targets. https://privateprofiteers.com
0 · Reply
Tokenist
Tokenist Nov. 12 at 12:40 PM
🚨EARNINGS ALERT🚨 Notable earnings released for today: GlobalFoundries Inc $GFS: $0.41 EPS vs $0.38 est. / $1.69B Revenue vs $1.68B est. Legend Biotech Corp $LEGN: -$0.11 EPS vs -$0.13 est. / $276.91M Revenue vs $272.33M est.
1 · Reply
VitalBull
VitalBull Nov. 12 at 12:12 PM
$LEGN https://www.globenewswire.com/news-release/2025/11/12/3186056/0/en/Legend-Biotech-Reports-Third-Quarter-2025-Results-and-Recent-Highlights.html
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:08 AM
$LEGN: The last close at $32.03 is slightly below the 30-day moving average (MA30) of $32.23, indicating a neutral to bearish short-term trend. The RSI at 49.0 suggests that the stock is neither overbought nor oversold, reinforcing a lack of strong directional momentum. The 50-day moving average (MA50) at $32.93 further indicates resistance above the current price. Given the 60-day high of $37.49 and low of $30.77, the stock is currently trading within this range, suggesting potential for a bounce back towards the upper end. Suggested entry: $32.10 (slightly above the last close). Stop: $30.70 (below the recent low). Targets: $34.00 (first target) and $36.00 (second target), aligning with resistance levels and potential retracement. Monitor market conditions closely as the stock approaches these targets. https://privateprofiteers.com
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Nov. 11 at 8:50 PM
$LEGN Investors should be furious at the complete incompetence of Legend Biotech’s management and Genscript. While the broader biotech sector is booming, $LEGN has gone nowhere. How do you fumble world-class science and a partnership with Johnson & Johnson this badly? No urgency. No communication. No shareholder value creation. Just silence while the market runs laps around them.
1 · Reply
VitalBull
VitalBull Nov. 10 at 11:25 PM
$LEGN👀 it's quiet in here.
2 · Reply
DiamondHandsBTW
DiamondHandsBTW Nov. 5 at 5:32 PM
$LEGN great company but really bad stock.
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Nov. 4 at 12:55 AM
$LEGN I’ve been tracking the recent hiring a lot lately. This company has a strong cash position of almost $1B with only $300MM in debt. To me it seems that this company is going to be buying something probs from China.
0 · Reply
Quantumup
Quantumup Nov. 3 at 12:06 PM
Canaccord Genuity⬆️ $ACLX's PT $130 from $121/reit'd Buy after conducting a detailed analysis of factors limiting $LEGN/ $JNJ CARVYKTI CART launch in MM, which all suggest favorable launch conditions for Arcellx in '26—based on its analysis of US CARVYKTI revs, the first 4Qs of the CARVYKTI rev could have been about 2x higher, accounting for issues w/ Out Of Specification (OOS) product, slow manufacturing time/infrastructure limitations We maintain our BUY rating and raise our price target on Arcellx to $130, based on higher anito-cel US launch revenues. We expect iMMagine-1's to show similar/better efficacy, and better safety vs. Legend/JnJ's CARTITUDE-1. We expect the ASH update in early December to reiterate the best-in-class profile of anito-cel. We also anticipate Kite's [ $GILD ] collaboration to support a smooth commercial launch in 4Q26. Arcellx currently holds ~$538M cash to support the company into 2028 for key data readouts and anito cel launch without additional fundraising.
0 · Reply
keypatience
keypatience Oct. 31 at 11:56 AM
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 29 at 5:28 PM
Updated analysis comparing SNDX's valuation as a multiple of projected revenues versus all peer commercial-stage oncology focused bios with market caps over $1B & 5 recent commercial-stage non-oncology focused peers with recent first approvals & revenue forecasts in the same ballpark as SNDX. $LEGN trades at the 2nd lowest multiple in the peer group followed by $JAZZ . JAZZ's multiples are calculated using its enterprise value. $ZYME trades at the highest revenue multiple in the oncology peer group. $BBIO trades at the highest in the 5 bio non-oncology focused peer group. We suspect BBIO revenue forecasts may be increased after reporting compelling data in muscular dystrophy this morning from its encaleret candidate. This is not investment advice.
0 · Reply